|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
University of Aarhus |
|---|---|
| Information provided by: | University of Aarhus |
| ClinicalTrials.gov Identifier: | NCT00463996 |
Purpose
Can MRI be used to stage ovarian cancer?
| Condition |
|---|
|
Ovarian Cancer |
| Study Type: | Observational |
| Study Design: | Screening, Longitudinal, Case Control, Prospective Study |
| Official Title: | Værdien af MRI Til Staging af c.Ovarii-et Prospektivt Studie |
| Estimated Enrollment: | 50 |
| Study Start Date: | April 2007 |
| Estimated Study Completion Date: | April 2008 |
Staging of ovarian cancer can best be performed with CT or MRI compared to ultrasound. Studies have shown an increase in pos. predictive value by adding contrast i.v. to the MR-examination protocol. We compare staging of ovarian cancer by 1.MRI without contrast (standard method) to 2.MRI with contrast agent i.v. (new method)in the same patient. Golden standard are findings at operation.
Eligibility| Genders Eligible for Study: | Female |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: Liselotte Ibsen, doc | +4589495201 | |
| Contact: Erik Lundorf, consultant | +4589495251 | elu@sks.aaa.dk |
| Principal Investigator: | Liselotte Ibsen, doc | Aarhus University Hospital, BDA, Skejby |
More Information
| Study ID Numbers: | MR-Center-001 |
| Study First Received: | April 18, 2007 |
| Last Updated: | April 18, 2007 |
| ClinicalTrials.gov Identifier: | NCT00463996 |
| Health Authority: | Denmark: Ethics Committee |
|
Ovarian cancer MRI Contrast agent |
|
Genital Diseases, Female Ovarian cancer Ovarian Neoplasms Gonadal Disorders Genital Neoplasms, Female |
Endocrine System Diseases Urogenital Neoplasms Endocrinopathy Ovarian Diseases Endocrine Gland Neoplasms |
|
Neoplasms Neoplasms by Site Adnexal Diseases |
